In contrast, after adding 20 mg/kg of monoclonal antibody against CD40 ligand to the regimen on days 0 and 2, we observed four thromboembolic complications in nine recipients. These included two ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. On a fourth-quarter earnings call with the media this morning ...

We then treated the mice with the standard regimen of Flt-3L and antibody to CD40, as well as DLI from clone 6.5 mice, then analyzed their spleens for expansion of clone 6.5 cells. A substantial ...